Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Periodontal Disease and Small Vulnerable Newborns in Rural Nepal
NCT07553286Phase 3Not yet recruiting
- Sponsor
- Johns Hopkins Bloomberg School of Public Health
- Start
- Dec 2026
- Primary completion
- Dec 2028
- Modality
- Conventional Liposomes, Small Molecules
01
Overview
Phase 3, randomised, open-label trial of cetylpyridinium chloride in preterm birth, Small for gestational age (SGA) and low birth weight (LBW) (2 arms), sponsored by Johns Hopkins Bloomberg School of Public Health. Primary endpoint: Proportion of small vulnerable newborn births. Planned start Dec 2026; status: not yet recruiting.
02
Drugs
cetylpyridinium chloride
03
Conditions
preterm birthSmall for gestational age (SGA)low birth weight (LBW)
Beyond the preview
Go deeper on NCT07553286.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07553286.